Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

702
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
702
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

762
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
762
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.4K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.4K
Pneumonia IV: Management01:28

Pneumonia IV: Management

731
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
731
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.5K
The pathophysiology of pneumonia involves the following steps:
2.5K
Longitudinal Research02:20

Longitudinal Research

13.0K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Marked Reduction in HIV/HCV Coinfections in Iceland Following the TraP HepC Nationwide Hepatitis C Elimination Program.

Open forum infectious diseases·2026
Same author

Intrahost Genomic Variation of Haemophilus influenzae Isolates from Asymptomatic Nasopharyngeal Carriers Involves Genes Encoding Proteins with Diverse Inferred Functions.

The American journal of pathology·2025
Same author

Changing Incidence, Aetiology and Outcomes of Prosthetic Joint Infections: A Population-Based Study in Iceland.

Journal of clinical medicine·2025
Same author

Clinically Important Decrease in Liver Stiffness Following Treatment for Hepatitis C: Outcome of the TraP HepC Nationwide Elimination Program.

Journal of clinical medicine·2025
Same author

Intra-host genomic variation of serologically nontypeable <i>Haemophilus influenzae</i> isolates from otitis media.

Microbiology spectrum·2025
Same author

A Striking Increase in Carriage Among Young Children in Iceland Paralleled the Unprecedented Increase of Invasive Group A Streptococcal Infection From 2022 to 2023.

The Pediatric infectious disease journal·2025

Related Experiment Video

Updated: Jan 9, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K

Disease Trends and Mortality From Invasive Pneumococcal Disease: A Long-Term Population-Based Study.

Hörður Tryggvi Bragason1,2, Kristján Godsk Rögnvaldsson1,2, Ubaldo Benitez Hernandez3

  • 1Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|December 6, 2025
PubMed
Summary
This summary is machine-generated.

Invasive pneumococcal disease (IPD) incidence declined, but short-term mortality remains unchanged. Survivors of pneumococcal pneumonia face significantly higher long-term mortality, highlighting the need for targeted interventions.

Keywords:
Streptococcus pneumoniaeepidemiologyinvasive pneumococcal diseasemortalityserotypes

More Related Videos

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

3.0K
Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae
09:12

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Published on: January 17, 2014

13.0K

Related Experiment Videos

Last Updated: Jan 9, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

3.0K
Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae
09:12

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Published on: January 17, 2014

13.0K

Area of Science:

  • Infectious Diseases
  • Epidemiology
  • Public Health

Background:

  • Streptococcus pneumoniae causes significant invasive pneumococcal disease (IPD) and mortality globally.
  • Pneumococcal conjugate vaccines (PCV) have reduced IPD incidence in many regions.
  • Long-term mortality trends in IPD survivors are not well-documented.

Purpose of the Study:

  • To analyze long-term mortality trends among IPD survivors in Iceland.
  • To compare all-cause mortality rates between IPD patients and the general population.
  • To assess the impact of PCV introduction on IPD mortality.

Main Methods:

  • Analysis of all IPD cases in Iceland (1975-2020) with positive blood/CSF cultures.
  • Assessment of 30-day and 5-year mortality rates across three decades (1985-2014).
  • Comparison of age-standardized all-cause mortality rates (ASRs) between IPD patients and the general population.

Main Results:

  • IPD incidence peaked in 1995-2004 and declined significantly post-2011 (p<.001).
  • No significant improvement in 30-day mortality was observed over time (p=.98).
  • IPD survivors had a 2.6-fold higher ASR for all-cause mortality compared to the general population (0.021 vs. 0.008 per person-year).

Conclusions:

  • Despite declining IPD incidence, short-term mortality has not improved.
  • A modest, non-significant improvement in 5-year mortality suggests potential benefits from chronic disease management.
  • IPD survivors experience substantially elevated long-term mortality, necessitating focused interventions to reduce both acute and long-term risks.